Alumis Inc

ALMS

Healthcare|Biotechnology|USA

$28.32

-1.96 (-6.48%)

Tangible Book

$4.06

About

Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.

Stock Price

+695.5%(1Y)

Pipeline Summary

13 total trials

Phase 1

Phase 2

Phase 3

Phase 4

Completed: 9Active: 3Terminated: 1

Active Trials (3)

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

NCT05966480SLE

Phase 2Active

Enrollment: 408 participants

Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

NCT06846541Plaque Psoriasis

Phase 3Active

Enrollment: 1,680 participants

Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis

NCT05739435Plaque Psoriasis

Phase 2Active

Enrollment: 165 participants

BioScore

4.3/10

Cautious

Ownership

Recent Insider Trades

Pangali SanamSELL

2026-07-065,000 shares @ $28

AKKARAJU SRINIVASBUY

2026-01-09588,235 shares @ $17

Foresite Capital Management VI LLCBUY

2026-01-08411,764 shares @ $17

Tananbaum James B.BUY

2026-01-08411,764 shares @ $17

Foresite Labs, LLCBUY

2026-01-08411,764 shares @ $17

Data last updated: Jul 13, 2026, 12:41 PM